Pathogen vaccines and methods of producing and using the same
The present invention provides vaccine compositions and methods of producing such compositions. Other embodiments of the invention include methods of treating a pathogen infection, methods of vaccinating a subject against a pathogen infection, and methods for treating an antibiotic-resistance bacterial infection in a subject in need thereof. In further embodiments, the invention includes methods of decreasing the level of a pathogen in a subject having a pathogen infection, methods of increasing the surviving rate of a subject having a pathogen infection, methods of reducing the level of pain associated with a pathogen infection, and methods of reducing the level of distress associated with a pathogen infection in a subject in need thereof. Novel scaffold compositions and opsonin-bound or lectin-bound pathogen compositions, and uses thereof, are also provided herein.
1. A vaccine composition, comprising
a scaffold comprising a biomaterial;
a lectin-bound pathogen construct encapsulated by the scaffold, wherein the lectin-bound pathogen construct comprises a solid substrate coupled to an immunoglobulin (IgG) Fc region fused to a lectin, or portion thereof; and a pathogen, or portion thereof, bound to the lectin, or portion thereof; and
a bioagent which recruits an immune cell and/or stimulates an immune response to the pathogen, or portion thereof, in the subject.
2. The vaccine composition of claim 1 , wherein the biomaterial is selected from the group consisting of glycosaminoglycan, silk, fibrin, the gelatinous protein mixture secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, poly-ethyleneglycol (PEG), polyhydroxy ethyl methacrylate, polyvinyl alcohol, polyacrylamide, poly (N-vinyl pyrolidone), poly(lactic acid), poly glycolic acid (PGA), poly lactic-co-glycolic acid (PLGA), poly e-carpolactone (PCL), polyethylene oxide, poly propylene fumarate (PPF), poly acrylic acid (PAA), polyhydroxybutyric acid, hydrolysed polyacrylonitrile, polymethacrylic acid, polyethylene amine, esters of alginic acid; pectinic acid; and alginate, fully or partially oxidized alginate, hyaluronic acid, carboxy methyl cellulose, heparin, heparin sulfate, chitosan, carboxymethyl chitosan, chitin, pullulan, gellan, xanthan, collagen, gelatin, carboxymethyl starch, carboxymethyl dextran, chondroitin sulfate, cationic guar, cationic starch, and combinations thereof.
3. The vaccine composition of claim 1 , wherein the biomaterial is selected from the group consisting of poly(L-lactide-co-glycolide) acid (PLGA), mesoporous silica, cryogel, and combinations thereof.
4. The vaccine composition of claim 1 , wherein the bioagent is selected from the group consisting of interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IL-17, IL-18, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, IFN-alpha, granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), Fms-related tyrosine kinase ligand (FTL)-3 ligand, CCL19, CCL21, M-SCF, MIF, CD40L, CD3, ICAM, transforming growth factor (TGF)-beta, cytosine-guanosine oligonucleotide (CpG-ODN), lipopolysaccharides (LPS), Fas ligand, Trail, lymphotactin, Mannan (M-FP), APG-2, Hsp70, Hsp90 and combinations thereof.
5. The vaccine composition of claim 1 , wherein the bioagent comprises an adjuvant.
6. The vaccine composition of claim 5 , wherein the adjuvant is selected from the group consisting of cytosine-guanosine oligonucleotide (CpG-ODN) sequence, granulocyte macrophage colony stimulating factor (GM-CSF), ovalbumin (OVA), monophosphoryl lipid A (MPL), poly(I:C), MF59, alum, aluminum hydroxide, aluminum phosphate, calcium phosphate hydroxide, Quil A, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), FIA, montanide, adjuvant 65, lipovant, poly (DL-lactide-coglycolide) microspheres, paraffin oil, squalene, virosome, AS03, ASO4, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IL-17, IL-18, STING, Toll-like receptor ligand, CD40L, pathogen-associated molecular patterns (PAMPs), damage-associated molecular pattern molecules (DAMPs), Freund's complete adjuvant, Freund's incomplete adjuvant, transforming growth factor (TGF)-beta antibody or antagonists, A2aR antagonists, lipopolysaccharides (LPS), Fas ligand, Trail, lymphotactin, Mannan (M-FP), APG-2, Hsp70, Hsp90, and combinations thereof.
7. The vaccine composition of claim 1 , wherein the lectin, or portion thereof, is an engineered lectin or portion thereof.
8. The vaccine composition of claim 1 , wherein the lectin or portion thereof is selected from the group consisting of a collectin, a ficollin, and a mannose-binding lectin (MBL) and combinations thereof.
9. The vaccine composition of claim 1 , wherein the solid substrate is selected from the group consisting of a magnetic bead, a microporous membrane, a hollow-fiber reactor, a blood filtration membrane and a blood flow device.
10. The vaccine composition of claim 1 , wherein the pathogen, or portion thereof, is an infectious microorganism selected from the group consisting of a bacterium, a fungus, a virus and a parasite, or a fragment thereof, and combinations thereof.
11. The vaccine composition of claim 1 , wherein the pathogen comprises a pathogen-associated molecule pattern (PAMP).
12. The vaccine composition of claim 11 , wherein the PAMP is selected from the group consisting of a pathogen fragment, a pathogen debris, a pathogen nucleic acid, a pathogen lipoprotein, a pathogen surface glycoprotein, a pathogen membrane component, a component released from the pathogen, and combinations thereof.
13. The vaccine composition of claim 1 , wherein the pathogen is in a sample derived from a subject; and/or wherein the pathogen is derived from an in vitro culture, a microorganism lysate, a crude lysate, or a purified lysate.
14. The vaccine composition of claim 1 , wherein the immune cell is an antigen-presenting cell.
15. The vaccine composition of claim 14 , wherein the immune cell is selected from the group consisting of a dendritic cell, a macrophage, a T cell, a B cell, and combinations thereof.
16. The vaccine composition of claim 1 , wherein the vaccine composition comprises at least two different types of pathogens.
17. The vaccine composition of claim 1 , wherein the vaccine composition is capable of targeting against different species of a pathogen.
18. The vaccine composition of claim 1 , wherein the vaccine composition is suitable for implantation in a subject; is suitable for injection in a subject; or is suitable for oral administration to a subject.
19. The vaccine composition of claim 18 , wherein the vaccine composition is suitable for subcutaneous implantation.
20. The vaccine composition of claim 18 , wherein the vaccine composition is in the form of a pill, a tablet, a capsule, a soft gel, a chewable, a powder, an emulsion, or an aqueous solution.
21. The vaccine composition of claim 1 , wherein the vaccine composition is lyophilized.
22. The vaccine composition of claim 21 , wherein the vaccine composition has a shelf life of about 30 days to about 1 year; or is capable of being stored at room temperature.
23. The vaccine composition of claim 1 , wherein the bioagent comprises granulocyte macrophage colony stimulating factor (GM-CSF).
24. The vaccine composition of claim 1 , wherein the bioagent comprises a cytosine-guanosine oligonucleotide (CpG-ODN) sequence.
25. The vaccine composition of claim 9 , wherein the solid substrate is a magnetic bead.
26. A vaccine composition, comprising a scaffold comprising a biomaterial selected from the group consisting of poly(L-lactide-co-glycolide) acid (PLGA), mesoporous silica, cryogel, and combinations thereof;
a lectin-bound pathogen construct encapsulated by the scaffold, wherein the lectin-bound pathogen construct comprises a solid substrate coupled to an immunoglobulin (IgG) Fc region fused to a lectin, or portion thereof; and a pathogen, or portion thereof, bound to the lectin, or portion thereof; and
a bioagent comprising granulocyte macrophage colony stimulating factor (GM-CSF) and/or a CpG-ODN sequence.
27. A kit for vaccinating a subject against a pathogen infection, comprising
a vaccine composition of claim 1 ; and
instructions for administering the vaccine to the subject.
28. A method of treating an antibiotic-resistant bacterial infection in a subject in need thereof, comprising administering the vaccine composition of claim 1 to the subject, thereby treating the antibiotic-resistant bacterial infection in the subject.
29. A method of increasing the survival rate of a subject having a pathogen infection, comprising administering the vaccine composition of claim 1 to the subject, thereby increasing the survival rate of the subject.
30. A method of treating a pathogen infection in a subject in need thereof, comprising administering the vaccine composition of claim 1 to the subject, thereby treating the pathogen infection in the subject.
31. A method of vaccinating a subject against a pathogen infection, comprising administering the vaccine composition of claim 1 to the subject, thereby vaccinating the subject against the pathogen infection.
32. A method of decreasing the level of a pathogen in a subject having a pathogen infection, comprising administering the vaccine composition of claim 1 to the subject, thereby decreasing the level of the pathogen in the subject.